ALK is a research-driven global pharmaceutical company focusing on allergy diagnosis and treatment. ALK is a world leader in allergy immunotherapy — a treatment of the underlying cause of allergy. The company has approximately 2,000 employees with subsidiaries, production facilities and distributors worldwide.
The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen.
ALK-Abelló Ltd is a member of the ABPI and abides by the Code of Practice for the Pharmaceutical Industry.
Disclosure of payments
made to HCPs and HCOs in the UK
Our 2016 transfers of value to individual Health Care Professionals (HCPs) and Health Care Organisation (HCOs) have been submitted to the ABPI disclosure database and is now available on their platform.
This link will take you to our disclosures for the UK: www.disclosureuk.org.uk
Patient Group Funding in the UK
In 2016 ALK UK Ltd made unrestricted grants totalling £52,790.00 to support various activities of the following patient support registered charities including The Anaphylaxis Campaign and Allergy UK.